<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.118547</article-id><article-id pub-id-type="publisher-id">ACM-44810</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210800000_86345689.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  高脂血症性急性胰腺炎合并动脉粥样硬化严重程度的相关分析
  Correlation Analysis of Hyperlipidemic Acute Pancreatitis with Atherosclerosis Severity
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>田</surname><given-names>飞</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>潇潇</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>自谦</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>潘</surname><given-names>越</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>潘</surname><given-names>新亭</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff2"><addr-line>青岛大学，山东 青岛</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>08</month><year>2021</year></pub-date><volume>11</volume><issue>08</issue><fpage>3731</fpage><lpage>3737</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：探讨高脂血症急性胰腺炎(HLAP)伴动脉粥样硬化(AS)的相关性分析。方法：回顾性分析2019年1月至2021年1月青岛大学附属医院全院急诊收治符合HLAP诊断标准的患者432例，并且其中伴AS患者120例，进行回顾性分析。按照既往是否诊断AS，将HLAP分为AS组(120例)和非AS组(312例)。比较两组一般资料、实验室指标、急性生理学和慢性健康状况评价II (acute physiology and chronic health evaluation II, APACHE II)、Balthazar CT评分。采用独立样本t检验、两样本秩和检验、卡方检验进行统计学比较，Kaplan-Meier生存曲线及Cox比例风险模型进行生存分析。结果：AS组与非AS组年龄、住院天数、复发次数、住院费用均有统计学意义(P均&lt;0.05)，而性别构成(X
  <sup>2</sup> = 1.459，P值 &gt; 0.05)差异无统计学意义。实验室检查指标中，AS组中与非AS组比较，低密度脂蛋白胆固醇(LDL-C)，高密度脂蛋白胆固醇(HDL-C)，总胆固醇(TC)，甘油三酯(TG)，游离脂肪酸(FFA)，脂蛋白a (LPa)，总胆汁酸(TBA)，总胆红素(TBIL)，直接胆红素(DBIL)，总钙(Ca)，肌酸激酶同工酶，胱抑素(Cys-C)，BMI (P均&lt;0.05)两者差异存在统计学意义。而对比前白蛋白(PA)，白蛋白(ALB)，肌酐(Crea)，肌酸激酶(CK) (P &gt; 0.05)差异无统计学意义。评分系统中AS组的Balthazar评分及APACHE II评分较非AS组升高(P &lt; 0.05)，差异具有统计学意义。入院后基本生命体征中，呼吸频率与体温两者比较存在差异，其余差异无统计学意义。Kaplan-Meier生存曲线，AS组较非AS组住院时间明显延长，AS组平均值为29.50，非AS组的平均值为12.57，
  X
  <sup>2</sup> = 111.26，P &lt; 0.001，95%置信区间(11.353, 13.786)。Cox比例风险模型，
  X
  <sup>2</sup> = 103.274，P &lt; 0.001。结论：AS是HLAP发生的危险因素，伴有AS的HLAP患者再发率明显升高，预后明显较差。
   Objective: To investigate the correlation between hyperlipidemic acute pancreatitis (HLAP) and atherosclerosis (AS). Methods: A total of 432 patients who met the diagnostic criteria of HLAP admitted to the Affiliated Hospital of Qingdao University from January 2019 to January 2021, including 120 patients with AS, were retrospectively analyzed. According to the previous diagnosis of AS, HLAP was divided into AS group (120 cases) and non-AS group (312 cases). General data, laboratory indicators, acute physiology and chronic health evaluation II (Apache Arch) and Balthazar CT scores were compared between the two groups. The independent sample t test, the rank sum test of the two samples and the chi-square test were used for statistical comparison. The Kaplan-Meier survival curve and Cox proportional risk model were used for survival analysis. Results: There were statistically significant differences in age, length of stay, frequency of recurrence and hospitalization cost between AS group and non-AS group (P &lt; 0.05), while there was no statistically significant difference in gender composition (P value &gt; 0.05). In the laboratory tests, compared with the non-AS group, low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), Total cholesterol (TC), triglyceride (TG), free fatty acid (FFA), Lipoprotein A (LPA), total bile acid (TBA), total bilirubin (TBIL), Direct bilirubin (DBIL), Total calcium (Ca), creatine kinase isoenzyme, Cystatin (Cys-C), BMI, (P &lt; 0.05). There was no significant difference in prealbumin (PA), albumin (ALB), creatinine (CREA) and creatine kinase (CK) (P &gt; 0.05). In the scoring system, Balthazar score and Apache II score in AS group were higher than those in non-AS group (P &lt; 0.05), and the differences were statistically significant. In the basic vital signs after admission, there were differences between respiratory rate and body temperature, while the other differences were not statistically significant. Kaplan-Meier survival curve showed that the hospital stay in the AS group was significantly longer than that in the non-AS group, the mean value of the AS group was 29.50, and the mean value of the non-AS group was 12.57, 
  X
  <sup>2</sup> = 111.26, P &lt; 0.001, 95% confidence interval (11.353, 13.786). Cox proportional risk model, 
  X
  <sup>2</sup> = 103.274, P &lt; 0.001. Conclusion: AS is a risk factor for the occurrence of HLAP, and the recurrence rate of HLAP patients with AS is significantly increased and the prognosis is significantly poor.
 
</p></abstract><kwd-group><kwd>高脂血症性急性胰腺炎，动脉粥样硬化，血脂, Hyperlipidemia Acute Pancreatitis</kwd><kwd> Atherosclerosis</kwd><kwd> Lipids</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨高脂血症急性胰腺炎(HLAP)伴动脉粥样硬化(AS)的相关性分析。方法：回顾性分析2019年1月至2021年1月青岛大学附属医院全院急诊收治符合HLAP诊断标准的患者432例，并且其中伴AS患者120例，进行回顾性分析。按照既往是否诊断AS，将HLAP分为AS组(120例)和非AS组(312例)。比较两组一般资料、实验室指标、急性生理学和慢性健康状况评价II (acute physiology and chronic health evaluation II, APACHE II)、Balthazar CT评分。采用独立样本t检验、两样本秩和检验、卡方检验进行统计学比较，Kaplan-Meier生存曲线及Cox比例风险模型进行生存分析。结果：AS组与非AS组年龄、住院天数、复发次数、住院费用均有统计学意义(P均&lt;0.05)，而性别构成(c<sup>2</sup> = 1.459，P值 &gt; 0.05)差异无统计学意义。实验室检查指标中，AS组中与非AS组比较，低密度脂蛋白胆固醇(LDL-C)，高密度脂蛋白胆固醇(HDL-C)，总胆固醇(TC)，甘油三酯(TG)，游离脂肪酸(FFA)，脂蛋白a (LPa)，总胆汁酸(TBA)，总胆红素(TBIL)，直接胆红素(DBIL)，总钙(Ca)，肌酸激酶同工酶，胱抑素(Cys-C)，BMI (P均&lt;0.05)两者差异存在统计学意义。而对比前白蛋白(PA)，白蛋白(ALB)，肌酐(Crea)，肌酸激酶(CK) (P &gt; 0.05)差异无统计学意义。评分系统中AS组的Balthazar评分及APACHE II评分较非AS组升高(P &lt; 0.05)，差异具有统计学意义。入院后基本生命体征中，呼吸频率与体温两者比较存在差异，其余差异无统计学意义。Kaplan-Meier生存曲线，AS组较非AS组住院时间明显延长，AS组平均值为29.50，非AS组的平均值为12.57，c<sup>2</sup> = 111.26，P &lt; 0.001，95%置信区间(11.353, 13.786)。Cox比例风险模型，c<sup>2</sup> = 103.274，P &lt; 0.001。结论：AS是HLAP发生的危险因素，伴有AS的HLAP患者再发率明显升高，预后明显较差。</p></sec><sec id="s2"><title>关键词</title><p>高脂血症性急性胰腺炎，动脉粥样硬化，血脂</p></sec><sec id="s3"><title>Correlation Analysis of Hyperlipidemic Acute Pancreatitis with Atherosclerosis Severity<sup> </sup></title><p>Fei Tian<sup>*</sup>, Xiaoxiao Wang<sup>*</sup>, Ziqian Wu, Yue Pan, Xinting Pan<sup>#</sup></p><p>Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/64-1572468x5_hanspub.png?20210827092148689" /></p><p>Received: Jul. 23<sup>rd</sup>, 2021; accepted: Aug. 19<sup>th</sup>, 2021; published: Aug. 26<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/64-1572468x6_hanspub.png?20210827092148689" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the correlation between hyperlipidemic acute pancreatitis (HLAP) and atherosclerosis (AS). Methods: A total of 432 patients who met the diagnostic criteria of HLAP admitted to the Affiliated Hospital of Qingdao University from January 2019 to January 2021, including 120 patients with AS, were retrospectively analyzed. According to the previous diagnosis of AS, HLAP was divided into AS group (120 cases) and non-AS group (312 cases). General data, laboratory indicators, acute physiology and chronic health evaluation II (Apache Arch) and Balthazar CT scores were compared between the two groups. The independent sample t test, the rank sum test of the two samples and the chi-square test were used for statistical comparison. The Kaplan-Meier survival curve and Cox proportional risk model were used for survival analysis. Results: There were statistically significant differences in age, length of stay, frequency of recurrence and hospitalization cost between AS group and non-AS group (P &lt; 0.05), while there was no statistically significant difference in gender composition (P value &gt; 0.05). In the laboratory tests, compared with the non-AS group, low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), Total cholesterol (TC), triglyceride (TG), free fatty acid (FFA), Lipoprotein A (LPA), total bile acid (TBA), total bilirubin (TBIL), Direct bilirubin (DBIL), Total calcium (Ca), creatine kinase isoenzyme, Cystatin (Cys-C), BMI, (P &lt; 0.05). There was no significant difference in prealbumin (PA), albumin (ALB), creatinine (CREA) and creatine kinase (CK) (P &gt; 0.05). In the scoring system, Balthazar score and Apache II score in AS group were higher than those in non-AS group (P &lt; 0.05), and the differences were statistically significant. In the basic vital signs after admission, there were differences between respiratory rate and body temperature, while the other differences were not statistically significant. Kaplan-Meier survival curve showed that the hospital stay in the AS group was significantly longer than that in the non-AS group, the mean value of the AS group was 29.50, and the mean value of the non-AS group was 12.57, c<sup>2</sup> = 111.26, P &lt; 0.001, 95% confidence interval (11.353, 13.786). Cox proportional risk model, c<sup>2</sup> = 103.274, P &lt; 0.001. Conclusion: AS is a risk factor for the occurrence of HLAP, and the recurrence rate of HLAP patients with AS is significantly increased and the prognosis is significantly poor.</p><p>Keywords:Hyperlipidemia Acute Pancreatitis, Atherosclerosis, Lipids</p><disp-formula id="hanspub.44810-formula32"><graphic xlink:href="//html.hanspub.org/file/64-1572468x7_hanspub.png?20210827092148689"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/64-1572468x8_hanspub.png?20210827092148689" /> <img src="//html.hanspub.org/file/64-1572468x9_hanspub.png?20210827092148689" /></p></sec><sec id="s5"><title>1. 引言</title><p>急性胰腺炎(acute pancreatitis, AP)是一种因胰腺局部炎症引发腹痛的临床常见急腹症，目前其发病率为(4.9~73.4)/10万，可能进一步引起全身炎症反应综合征，发展为多器官功能衰竭，进展为重症急性胰腺炎(sever acute pancreatitis, SAP)死亡率20%~30%。基于中国慢性病及其危险因素监测(CCDRFS)项目的数据，目前我国标化的平均BMI：从2004年的22.7 m/Kg<sup>2</sup> (95%CI 22.5~22.9)上升到2018年的24.4 m/Kg<sup>2</sup> (24.3~24.6)，标化肥胖率从3.1% (2.5~3.7)增加至8.1% (7.6~8.7) [<xref ref-type="bibr" rid="hanspub.44810-ref1">1</xref>]。高甘油三酯引起的胰腺炎所占比重较前明显增多，一项大样本研究表明其占胰腺炎比例已跃升至25.6%，高脂血症性胰腺炎(hyperlipidemic acute pancreatitis, HLAP)往往更容易进展为SAP [<xref ref-type="bibr" rid="hanspub.44810-ref2">2</xref>]。动脉粥样硬化(AS)是以进行性脂质沉积、纤维组织增生和炎细胞浸润为特征的累及全身大、中型弹性和肌性动脉的慢性疾病 [<xref ref-type="bibr" rid="hanspub.44810-ref3">3</xref>]。血脂代谢异常导致脂质沉积于各级血管，破坏血管壁完整性，影响血液流动性，进一步诱发急性胰腺炎的发生。</p><p>目前已有研究表明动脉粥样硬化与HLAP存在一定关联 [<xref ref-type="bibr" rid="hanspub.44810-ref4">4</xref>]，在临床诊治过程中也多有验证HLAP患者多并发心血管相关损伤，并且进展为SAP相对于其他病因可能性大，预后更差。目前临床诊治过程中多数忽略AS对AP预后的关注，但AP进一步发展为SAP后治疗难度大，预后差，死亡率高，若能对存在AS的HLAP进行早期识别、积极干预，则可不同程度改善患者预后。</p></sec><sec id="s6"><title>2. 对象与方法</title><p>(一) 研究对象</p><p>选择2019年1月至2021年1月在青岛大学附属医院急诊收治HLAP患者432例，其中伴有AS确诊患者120例。纳入标准：1) HLAP符合《中国急性胰腺炎诊治指南(2021)》 [<xref ref-type="bibr" rid="hanspub.44810-ref5">5</xref>] 诊断标准和分级标准；2) AS符合《中国血脂异常与动脉粥样硬化性心血管疾病防控的新证据和新指南》 [<xref ref-type="bibr" rid="hanspub.44810-ref6">6</xref>]。3) 临床资料完整。排除标准：1) 慢性胰腺炎或其他慢性炎症。2) 糖尿病、高血压、自身免疫病及病毒感染性疾病。3) 妊娠期。4) 放弃治疗或死亡。</p><p>(二) 研究方法</p><p>符合HLAP诊断标准者，根据超声、造影、实验室检查及临床表现将存在主动脉、冠状动脉、颅脑动脉、肾动脉肠系膜动脉、四肢动脉粥样硬化者划归为AS组(120例)和非AS组(312例)。比较AS组与非AS组的一般资料，实验室检查指标和其他资料。一般资料包括性别、年龄、住院时间、住院费用、出院诊断、既往胰腺炎发作史(既往发作胰腺炎 ≥ 1次)。实验室检查均取入院24小时内最严重的值，包括低密度脂蛋白胆固醇(LDL-C)，前白蛋白(PA)，总胆固醇(TC)，总胆汁酸(TBA)，总胆红素(TBIL)，总钙(Ca)，游离脂肪酸(FFA)，甘油三酯(TG)，白蛋白(ALB)，直接胆红素(DBIL)，肌酐(Crea)，肌酸激酶(CK)，肌酸激酶同工酶，脂蛋白a (LPa)，胱抑素(Cys-C)，高密度脂蛋白胆固醇(HDL-C)，BMI及生命体征。其他资料包括急性生理学和慢性健康状况评价II (acute physiology and chronic health evaluation II, APACHE II)、Balthazar CT评分。</p><p>(三) 统计学方法</p><p>应用SPSS24.0软件进行统计学分析。符合正态分布的计量资料采用独立样本t检验，以 X &#175; &#177; S表示，计数资料采用卡方检验，以百分位数表示。Kaplan-Meier法进行生存分析。多因素COX回归分析AP预后的影响因素。检验水准α = 0.05。根据预实验及相关文献计算样本量。根据以连续变量为比较的诊断性研究计算方法，AS组的复发次数均数为2.6，标准差为2.05，调整相对允许误差为0.1，绝对允许误差为0.1，参数α为0.05，采用双侧计算，失访比例设置为0.1，所计算的样本量110人。同样的，非AS组的复发次数均数设置为4.76，标准差为1.60，其余指标同重症急性胰腺炎，计算出的样本人数为311人。</p></sec><sec id="s7"><title>3. 结果</title><p>(一) AS组与非AS组一般资料、实验室检查指标和其他资料比较</p><p>见表1，AS组与非AS组年龄、住院天数、复发次数、住院费用均有统计学意义(t = −10.614，−2.676，−10.351，−3.521，P均&lt;0.05)，而性别构成(c<sup>2</sup> = 1.459，P值 &gt; 0.05)差异无统计学意义。</p><p>见表1，实验室检查指标中，AS组中与非AS组比较，低密度脂蛋白胆固醇(LDL-C) (2.36 &#177; 0.95~2.59 &#177; 1.14)，高密度脂蛋白胆固醇(HDL-C) (1.04 &#177; 0.22~1.17 &#177; 0.44)，总胆固醇(TC) (3.85 &#177; 1.34~4.80 &#177; 2.33)，甘油三酯(TG) (1.27 &#177; 0.67~2.79 &#177; 4.93)，游离脂肪酸(FFA) (0.94 &#177; 0.56~0.59 &#177; 0.34)，脂蛋白a (LPa) (210.19 &#177; 172.16~158.61 &#177; 168.73)，总胆汁酸(TBA) (3.91 &#177; 2.85~7.29 &#177; 26.56)，总胆红素(TBIL) (19.40 &#177; 13.05~25.13 &#177; 22.93)，直接胆红素(DBIL) (8.25 &#177; 9.32~10.95 &#177; 15.73)，总钙(Ca) (2.11 &#177; 0.173~2.06 &#177; 0.179)，肌酸激酶同工酶(14.65 &#177; 9.23~11.37 &#177; 7.26)，胱抑素(Cys-C) (1.15 &#177; 0.33~0.84 &#177; 0.42)，BMI (24.50 &#177; 3.77~28.60 &#177; 5.35)，(t = 1.985，4.04，4.193，5.333，−6.375，2.816，2.158，3.247，2.193，−2.751，−3.533，−7.796，0.988，P均&lt;0.05)两者差异存在统计学意义。而对比前白蛋白(PA)，白蛋白(ALB)，肌酐(Crea)，肌酸激酶(CK) (P &gt; 0.05)差异无统计学意义。</p><p>见表1，评分系统中AS组的Balthazar评分(3.74 &#177; 2.82~2.59 &#177; 2.34)及APACHE II评分(23.28 &#177; 10.57~7.52 &#177; 5.92)较非AS组升高(t = −3.447, −15.414, P &lt; 0.05)差异具有统计学意义。入院后基本生命体征中，呼吸频率与体温两者比较存在差异，其余差异无统计学意义。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of statistical data and indicators between the two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >指标</th><th align="center" valign="middle" >AS组</th><th align="center" valign="middle" >非AS组</th><th align="center" valign="middle" >统计值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >(n = 120)</td><td align="center" valign="middle" >(n = 312)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >性别(例，%) 男 女</td><td align="center" valign="middle" >80，66.7 40，33.3</td><td align="center" valign="middle" >190，61.1 120，38.6</td><td align="center" valign="middle" >1.459</td><td align="center" valign="middle" >0.482</td></tr><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" >73.96 &#177; 13.81</td><td align="center" valign="middle" >55.04 &#177; 17.54</td><td align="center" valign="middle" >−10.614</td><td align="center" valign="middle" >*</td></tr><tr><td align="center" valign="middle" >住院天数(天)</td><td align="center" valign="middle" >12.33 &#177; 8.274</td><td align="center" valign="middle" >10.32 &#177; 6.42</td><td align="center" valign="middle" >−2.676</td><td align="center" valign="middle" >0.008</td></tr><tr><td align="center" valign="middle" >复发次数(次)</td><td align="center" valign="middle" >4.76 &#177; 1.60</td><td align="center" valign="middle" >2.60 &#177; 2.05</td><td align="center" valign="middle" >−10.351</td><td align="center" valign="middle" >*</td></tr><tr><td align="center" valign="middle" >住院费用(元)</td><td align="center" valign="middle" >39,686.75 &#177; 59,354.51</td><td align="center" valign="middle" >24,934.05 &#177; 27,400.84</td><td align="center" valign="middle" >−3.521</td><td align="center" valign="middle" >*</td></tr><tr><td align="center" valign="middle" >低密度脂蛋白胆固醇(LDL-C)，mmol/L</td><td align="center" valign="middle" >2.36 &#177; 0.95</td><td align="center" valign="middle" >2.59 &#177; 1.14</td><td align="center" valign="middle" >1.985</td><td align="center" valign="middle" >0.048</td></tr><tr><td align="center" valign="middle" >高密度脂蛋白胆固醇(HDL-C)，mmol/L</td><td align="center" valign="middle" >1.04 &#177; 0.22</td><td align="center" valign="middle" >1.17 &#177; 0.44</td><td align="center" valign="middle" >4.04</td><td align="center" valign="middle" >*</td></tr><tr><td align="center" valign="middle" >前白蛋白(PA)，mg/L</td><td align="center" valign="middle" >171.58 &#177; 84.97</td><td align="center" valign="middle" >160.34 &#177; 71.01</td><td align="center" valign="middle" >−1.385</td><td align="center" valign="middle" >0.167</td></tr><tr><td align="center" valign="middle" >白蛋白(ALB)，g/L</td><td align="center" valign="middle" >42.68 &#177; 11.24</td><td align="center" valign="middle" >40.77 &#177; 10.04</td><td align="center" valign="middle" >−1.714</td><td align="center" valign="middle" >0.087</td></tr><tr><td align="center" valign="middle" >总胆固醇(TC)，mmol/L</td><td align="center" valign="middle" >3.85 &#177; 1.34</td><td align="center" valign="middle" >4.80 &#177; 2.33</td><td align="center" valign="middle" >4.193</td><td align="center" valign="middle" >*</td></tr><tr><td align="center" valign="middle" >甘油三酯(TG)，mmol/L</td><td align="center" valign="middle" >1.27 &#177; 0.67</td><td align="center" valign="middle" >2.79 &#177; 4.93</td><td align="center" valign="middle" >5.333</td><td align="center" valign="middle" >*</td></tr><tr><td align="center" valign="middle" >游离脂肪酸(FFA)，mmol/L</td><td align="center" valign="middle" >0.94 &#177; 0.56</td><td align="center" valign="middle" >0.59 &#177; 0.34</td><td align="center" valign="middle" >−6.375</td><td align="center" valign="middle" >*</td></tr><tr><td align="center" valign="middle" >脂蛋白a (LPa)，mg/L</td><td align="center" valign="middle" >210.19 &#177; 172.16</td><td align="center" valign="middle" >158.61 &#177; 168.73</td><td align="center" valign="middle" >−2.816</td><td align="center" valign="middle" >0.005</td></tr><tr><td align="center" valign="middle" >总胆汁酸(TBA)，umol/L</td><td align="center" valign="middle" >3.91 &#177; 2.85</td><td align="center" valign="middle" >7.29 &#177; 26.56</td><td align="center" valign="middle" >2.158</td><td align="center" valign="middle" >0.032</td></tr><tr><td align="center" valign="middle" >总胆红素(TBIL)，umol/L</td><td align="center" valign="middle" >19.40 &#177; 13.05</td><td align="center" valign="middle" >25.13 &#177; 22.93</td><td align="center" valign="middle" >3.247</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >直接胆红素(DBIL)，umol/L</td><td align="center" valign="middle" >8.25 &#177; 9.32</td><td align="center" valign="middle" >10.95 &#177; 15.73</td><td align="center" valign="middle" >2.193</td><td align="center" valign="middle" >0.029</td></tr><tr><td align="center" valign="middle" >总钙(Ca)，mmol/L</td><td align="center" valign="middle" >2.11 &#177; 0.173</td><td align="center" valign="middle" >2.06 &#177; 0.179</td><td align="center" valign="middle" >−2.751</td><td align="center" valign="middle" >0.006</td></tr><tr><td align="center" valign="middle" >肌酐(Crea)，μmol/L</td><td align="center" valign="middle" >91.30 &#177; 39.47</td><td align="center" valign="middle" >81.47 &#177; 54.59</td><td align="center" valign="middle" >−1.792</td><td align="center" valign="middle" >0.074</td></tr><tr><td align="center" valign="middle" >肌酸激酶(CK)，U/L</td><td align="center" valign="middle" >99.22 &#177; 50.72</td><td align="center" valign="middle" >93.61 &#177; 138.35</td><td align="center" valign="middle" >−0.574</td><td align="center" valign="middle" >0.567</td></tr><tr><td align="center" valign="middle" >肌酸激酶同工酶，U/L</td><td align="center" valign="middle" >14.65 &#177; 9.23</td><td align="center" valign="middle" >11.37 &#177; 7.26</td><td align="center" valign="middle" >−3.533</td><td align="center" valign="middle" >*</td></tr><tr><td align="center" valign="middle" >胱抑素(Cys-C)，mg/L</td><td align="center" valign="middle" >1.15 &#177; 0.33</td><td align="center" valign="middle" >0.84 &#177; 0.42</td><td align="center" valign="middle" >−7.796</td><td align="center" valign="middle" >*</td></tr><tr><td align="center" valign="middle" >身高，米</td><td align="center" valign="middle" >1.67 &#177; 0.06</td><td align="center" valign="middle" >1.67 &#177; 0.11</td><td align="center" valign="middle" >0.07</td><td align="center" valign="middle" >0.944</td></tr><tr><td align="center" valign="middle" >体重，公斤</td><td align="center" valign="middle" >68.63 &#177; 12.37</td><td align="center" valign="middle" >73.83 &#177; 16.07</td><td align="center" valign="middle" >3.589</td><td align="center" valign="middle" >*</td></tr><tr><td align="center" valign="middle" >BMI，Kg/m&#178;</td><td align="center" valign="middle" >24.50 &#177; 3.77</td><td align="center" valign="middle" >28.60 &#177; 5.35</td><td align="center" valign="middle" >0.988</td><td align="center" valign="middle" >*</td></tr><tr><td align="center" valign="middle" >体温，℃</td><td align="center" valign="middle" >36.55 &#177; 0.44</td><td align="center" valign="middle" >36.74 &#177; 0.58</td><td align="center" valign="middle" >3.566</td><td align="center" valign="middle" >*</td></tr><tr><td align="center" valign="middle" >脉搏，次/分</td><td align="center" valign="middle" >79.83 &#177; 18.24</td><td align="center" valign="middle" >81.86 &#177; 17.19</td><td align="center" valign="middle" >1.076</td><td align="center" valign="middle" >0.283</td></tr><tr><td align="center" valign="middle" >呼吸，次/分</td><td align="center" valign="middle" >18.29 &#177; 2.38</td><td align="center" valign="middle" >19.08 &#177; 3.43</td><td align="center" valign="middle" >2.704</td><td align="center" valign="middle" >0.007</td></tr><tr><td align="center" valign="middle" >收缩压，mmHg</td><td align="center" valign="middle" >137.96 &#177; 21.35</td><td align="center" valign="middle" >134.40 &#177; 20.02</td><td align="center" valign="middle" >−1.625</td><td align="center" valign="middle" >0.105</td></tr><tr><td align="center" valign="middle" >舒张压，mmHg</td><td align="center" valign="middle" >76.96 &#177; 14.69</td><td align="center" valign="middle" >79.06 &#177; 11.74</td><td align="center" valign="middle" >1.403</td><td align="center" valign="middle" >0.122</td></tr><tr><td align="center" valign="middle" >Balthazar评分</td><td align="center" valign="middle" >3.74 &#177; 2.82</td><td align="center" valign="middle" >2.59 &#177; 2.34</td><td align="center" valign="middle" >−3.447</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >APACHE II评分</td><td align="center" valign="middle" >23.28 &#177; 10.57</td><td align="center" valign="middle" >7.52 &#177; 5.92</td><td align="center" valign="middle" >−15.414</td><td align="center" valign="middle" >*</td></tr></tbody></table></table-wrap><p>表1. 两组统计学数据指标比较</p><p>*: &lt;0.001.</p><p>图1. AS组与非AS组Kaplan-Meier生存曲线比较</p><p>图1中可见AS组较非AS组住院时间明显延长，差异具有统计学意义。</p><p>图2. AS组与非AS组的COX生存分析曲线</p><p>图2数据显示，纳入了总胆固醇、甘油三酯、游离脂肪酸三种危险因素后，两组比较结果差异具有统计学意义。</p></sec><sec id="s8"><title>4. 讨论</title><p>目前主流观点认为急性胰腺炎主要病理改变为胰腺自身溶解，同时伴有脂肪酶造成的局灶性脂肪坏死及炎细胞浸润。本项研究主要考虑腺体血栓形成，造成胰腺微循环障碍，导致胰腺坏死加重。目前我们仍不清楚HLAP确切的病理生理机制，主流的理论存在三个。首先，血脂升高会影响胰腺炎微循环。血脂过高会损伤血管内皮细胞，改变血管壁的通透性，导致血栓形成 [<xref ref-type="bibr" rid="hanspub.44810-ref7">7</xref>]。其次，血脂升高会导致游离脂肪酸增多。多余的游离脂肪酸进一步会诱发酸中毒，同时激活胰蛋白酶，破坏腺细胞及导管间的紧密连接，使脂肪酶漏入组织间隙加剧自身消化 [<xref ref-type="bibr" rid="hanspub.44810-ref8">8</xref>]。最后，游离脂肪酸(FFA)入血后直接损伤胰腺细胞 [<xref ref-type="bibr" rid="hanspub.44810-ref9">9</xref>]。动脉粥样硬化(AS)主要反映出机体长期脂质代谢异常导致血管内膜结构或功能受损，致使通透性发生改变，血脂异常沉积到血管壁的渐进性病理过程，脂质代谢异常持续时间长，程度高，动脉粥样硬化病变愈严重 [<xref ref-type="bibr" rid="hanspub.44810-ref10">10</xref>]。重症急性胰腺炎(sever acute pancreatitis, SAP)时，可导致心脏明显受损，如心肌梗死、心内膜炎或传导系统异常 [<xref ref-type="bibr" rid="hanspub.44810-ref11">11</xref>]。胰脂肪酶进入血液循环到达心脏后引起心外膜脂肪坏死 [<xref ref-type="bibr" rid="hanspub.44810-ref12">12</xref>]。</p><p>本次研究表明，既往患有AS的HLAP患者，住院时间明显延长，发病次数明显增多，血钙升高，APACHE II评分及Balthazar评分均高于非AS患者。多项研究报道，高血钙、APACHE II评分及Balthazar评分均与AP的严重程度相关，并且高血钙对AP的预后有明显的预测作用 [<xref ref-type="bibr" rid="hanspub.44810-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.44810-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.44810-ref15">15</xref>]。</p><p>本研究与当前多数报道结果相近，但发现异常表现，AS组胆固醇、甘油三酯较非AS组明显降低，而AS组游离脂肪酸较非AS组异常升高。根据当前的研究，AS患者根据指南常规进行降脂治疗 [<xref ref-type="bibr" rid="hanspub.44810-ref16">16</xref>]，致使胆固醇及甘油三酯水平较低，但根据本项研究，降脂治疗后AS组患者AP的复发率较非AS组患者仍然较高，且预后较差。当前一些研究团队认为降低AS患者血脂水平并未纠正机体的脂质代谢异常 [<xref ref-type="bibr" rid="hanspub.44810-ref17">17</xref>]，AS患者长期存在脂质代谢异常，这可能成为HLAP的发病基础。长期的血脂异常会导致胰腺微循环血管损伤、微血栓逐渐累积，短期未见明显异常症状，在患者进一步暴饮暴食、饮酒或胆囊结石诱发，胰腺分泌受阻进而爆发急性胰腺炎。而胰腺小叶的血供属终动脉结构，即由独支小叶内动脉供血，并且相邻小叶内动及其分支间不存在吻合支，所以胰腺微循环障碍时小叶缺血坏死。当胰腺微循环存在广泛血管损伤、微血栓阻塞，极易在急性胰腺炎爆发后出现胰腺坏死，最终进展为重症急性胰腺炎。即使未进展为重症急性胰腺炎，AS患者存在的脂质代谢异常也会影响胰腺微循环功能，导致急性胰腺炎反复发作。临床观察发现，排除先天脂质代谢异常、胰管发育异常导致的急性胰腺炎外，多数反复发作的急性胰腺炎患者发病时并未存在暴饮暴食、大量饮酒及胆囊结石等诱因。考虑由于长期脂质代谢异常导致微循环障碍，导致胰腺血运受阻，胰腺分泌受损伴有局部组织坏死，最终导致胰腺炎反复发作。</p><p>进行本研究过程中发现部分患者再发急性胰腺炎时，并未存在暴饮暴食、饮酒及胆囊结石等诱发因素，血脂水平正常，考虑为长期血脂异常导致胰腺微循环血管受损，间断造成胰腺局部缺血，诱发急性胰腺炎，但缺少相关研究，需要进一步临床试验进行观察。</p><p>本次研究存在一定的局限性：本研究病例收集时间跨度大，不能除外不同实验室检查对实验结果的影响。本研究为回顾性研究，并且应用的非客观参数可能会对结论带来不确定影响。</p><p>综上所述，AS是HLAP发生的危险因素，伴有AS的HLAP患者再发率明显升高，预后明显较差。</p></sec><sec id="s9"><title>利益冲突</title><p>所有作者均声明不存在利益冲突。</p></sec><sec id="s10"><title>文章引用</title><p>田 飞,王潇潇,吴自谦,潘 越,潘新亭. 高脂血症性急性胰腺炎合并动脉粥样硬化严重程度的相关分析 Correlation Analysis of Hyperlipidemic Acute Pancreatitis with Atherosclerosis Severity[J]. 临床医学进展, 2021, 11(08): 3731-3737. https://doi.org/10.12677/ACM.2021.118547</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44810-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Wang, L., Zhou, B., Zhao, Z., et al. (2021) Body-Mass Index and Obesity in Urban and Rural China: Findings from Consecutive Nationally Representative Surveys during 2004-18. Lancet (London, England), 398, 53-63. 
&lt;br&gt;https://doi.org/10.1016/S0140-6736(21)00798-4</mixed-citation></ref><ref id="hanspub.44810-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Chuang, S.C., Lee, K.T., Wang, S.N., Kuo, K.K. and Chen, J.S. (2006) Hypertriglyceridemia-Associated Acute Pancreatitis with Chylous Ascites in Pregnancy. Journal of the Formosan Medical Association, 105, 583-587. 
&lt;br&gt;https://doi.org/10.1016/S0929-6646(09)60154-6</mixed-citation></ref><ref id="hanspub.44810-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">张运. 动脉粥样硬化研究的当前问题[J]. 中华心血管病杂志, 2011, 9(39): 785-788.</mixed-citation></ref><ref id="hanspub.44810-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">赵丹丹, 张玫. 中老年急性胰腺炎患者临床特点分析[J]. 中国医药, 2021, 16(3): 397-399.</mixed-citation></ref><ref id="hanspub.44810-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">谢宇, 孙备. 胰腺炎基础研究进展与展望[J]. 中国实用外科杂志, 2021, 41(1): 60-65.</mixed-citation></ref><ref id="hanspub.44810-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">胡大一. 中国血脂异常与动脉粥样硬化性心血管疾病防控的新证据和新指南[J]. 中华心血管病杂志, 2016, 44(10): 826-827.</mixed-citation></ref><ref id="hanspub.44810-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Havel, R.J. (1969) Pathogenesis, Differentiation and Management of Hypertriglyceridemia. Advances in Internal Medicine, 15, 117-154.</mixed-citation></ref><ref id="hanspub.44810-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Yang, A.L. and McNabb-Baltar, J. (2020) Hypertriglyceridemia and Acute Pancreatitis. Pancreatology, 20, 795-800. 
&lt;br&gt;https://doi.org/10.1016/j.pan.2020.06.005</mixed-citation></ref><ref id="hanspub.44810-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Z¢dori, N., Gede, N., Antal, J., et al. (2020) Early Elimination of Fatty Acids in Hypertriglyceridemia-Induced Acute Pancreatitis (ELEFANT Trial): Protocol of an Open-Label, Multicenter, Adaptive Randomized Clinical Trial. Pancreatology, 20, 369-376. &lt;br&gt;https://doi.org/10.1016/j.pan.2019.12.018</mixed-citation></ref><ref id="hanspub.44810-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">郭明秋, 殷晓捷, 刁殿琰, 原江水. 脂质代谢水平与冠状动脉粥样硬化病变的关系[J]. 中国动脉硬化杂志, 2021, 29(2): 149-155.</mixed-citation></ref><ref id="hanspub.44810-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Prasada, R., Dhaka, N., Bahl, A., Yadav, T.D. and Kochhar, R. (2018) Prevalence of Cardiovascular Dysfunction and Its Association with Outcome in Patients with Acute Panc Reatitis. Indian Journal of Gastroenterology, 37, 113-119. 
&lt;br&gt;https://doi.org/10.1007/s12664-018-0826-0</mixed-citation></ref><ref id="hanspub.44810-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">王蔚虹. 重视重症急性胰腺炎心脏损伤的诊治[J]. 中华消化杂志, 2019, 39(5): 294-297.</mixed-citation></ref><ref id="hanspub.44810-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">李若畅, 张景丽, 李瑞, 等. 急性胰腺炎并发门静脉系统血栓152例临床特点和临床预测[J]. 中华消化杂志, 2021, 41(1): 29-34.</mixed-citation></ref><ref id="hanspub.44810-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">李曼, 邢小康, 郭丰. 6种评分系统和4个实验室检查指标对重症急性胰腺炎预后的评估作用[J]. 中华消化杂志, 2018, 38(10): 673-677.</mixed-citation></ref><ref id="hanspub.44810-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">陈方莹, 柏小寅, 吴东. 预测急性胰腺炎严重程度的评分系统及生物标志物[J]. 中华内科杂志, 2019, 58(8): 615-619.</mixed-citation></ref><ref id="hanspub.44810-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">第二次中国临床血脂控制状况多中心协作研究组. 第二次中国临床血脂控制达标率及影响因素多中心协作研究[J]. 中华心血管病杂志, 2007, 35(5): 420-427.</mixed-citation></ref><ref id="hanspub.44810-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">刘浩, 余金明, 陈芳, 潘长玉, 李觉, 胡大一. 冠心病患者血脂代谢异常的流行病学研究[J]. 中国实用内科杂志, 2007, 27(12): 965-967.</mixed-citation></ref></ref-list></back></article>